Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Low Ankle-Brachial Index Associated With Rise in Creatinine Level Over Time

Low Ankle-Brachial Index Associated With Rise in Creatinine Level Over Time BackgroundA low ankle-brachial index (ABI) predicts risk of cardiovascular death, myocardial infarction, peripheral arterial disease events, and stroke. However, it is unknown whether a low ABI also predicts a decline in renal function.MethodsWe examined the association between ABI and change in serum creatinine level over time among 13 655 participants in the Atherosclerosis Risk in Communities (ARIC) study who underwent serum creatinine and ABI measurement at baseline and also underwent serum creatinine measurement 3 years later at the second study visit. The study outcome was a 50% rise in serum creatinine level from baseline to the second study visit.ResultsOverall, 0.48% of participants with an ABI of 1 or higher, 0.9% of participants with an ABI between 0.9 and 0.99, and 2.16% of participants with an ABI lower than 0.9 experienced a 50% or greater increase in serum creatinine level. In multivariate analysis, participants with an ABI lower than 0.9 were still more than twice as likely as those in the referent category (ABI ≥1) to experience an increase in serum creatinine level (odds ratio 2.5; 95% confidence interval, 1.1-5.7) (P = .04), and a linear trend in the incidence of worsening renal function was noted across ABI categories (P = .02). Analyses excluding participants with renal insufficiency, diabetes, and hypertension at baseline all produced similar results.ConclusionIn addition to known associations of the ABI with stroke, myocardial infarction, peripheral arterial disease events, and cardiovascular death, a low ABI also predicts an increase in serum creatinine level over time.The prevalence and incidence of cardiovascular disease are both high among those with renal insufficiency,and chronic kidney disease and cardiovascular disease share many of the same risk factors.However, the contribution of preexisting cardiovascular disease to progression of renal disease has not been examined in detail.We hypothesized that a low ankle-brachial index (ABI)—a marker for both lower extremity and more generalized atherosclerotic diseaseand a known predictor of cardiovascular death, myocardial infarction, peripheral arterial disease events, and stroke—would also be associated with a decline in renal function over time. We tested this hypothesis using publicly available data from the first and second study visits of the Atherosclerosis Risk in Communities (ARIC) study.METHODSThe ARIC studywas a prospective cohort study of cardiovascular disease among a community sample of middle-aged residents of Jackson, Miss; Forsyth County, North Carolina; Washington County, Maryland; and several suburbs of Minneapolis, Minn. The study consisted of 15 792 men and women aged 45 to 64 years at baseline. Participant recruitment and baseline data collection were completed between 1987 and 1989, and participants subsequently returned for 3 visits, each spaced 3 years apart. The present analysis uses publicly available data from the first and second study visits and was approved by the institutional review board at the University of California, San Francisco.OUTCOME MEASURE AND PREDICTOR VARIABLESThe primary predictor variable for the present analysis was ABI at the first study visit. The ABI is the ratio of systolic blood pressure at the ankle to systolic blood pressure at the brachial artery. Ankle and brachial systolic blood pressure measurements were ascertained using the Dinamap 1846 SX (Critixon, Tampa, Fla). Ankle blood pressure was measured at the posterior tibial artery in one leg. Two measurements were taken 5 to 8 minutes apart while the participant was in the prone position. Brachial artery systolic blood pressure measurements were taken 5 minutes apart with the participant in the supine position. The ABI was computed by dividing the average of the 2 ankle systolic blood pressure measurements by the average of the first 2 brachial readings. For the purposes of this analysis, we divided ABI measurements into 3 categories at the clinically established cutoffs of 0.9 and 1.0.The outcome measure for the present analysis was the occurrence of at least a 50% rise in serum creatinine level between baseline and the first follow-up visit approximately 3 years later. Too few participants experienced a doubling of serum creatinine level (a more conventional measure of renal functional decline) during follow-up for this to be used as an outcome. Regardless of initial creatinine level, a 50% increase in serum creatinine level translates into an approximately 25% decrease in creatinine clearance. This outcome is more easily interpreted than either a fixed increase in serum creatinine level or a fixed decrease in estimated creatinine clearance or glomerular filtration rate. The correlation between fixed increases in serum creatinine level and creatinine clearance is highly variable, depending on the initial creatinine level, and since values can be very inflated in patients with normal renal function, fixed decrements over time in calculated creatinine clearance or glomerular filtration rate may be misleading.Our analysis was adjusted for the following covariates ascertained at visit 1: demographic characteristics (age, race [black vs nonblack], and sex), baseline Cockcroft-Gault–estimated creatinine clearance,comorbid conditions including diabetes (previously diagnosed or fasting glucose level ≥126 mg/dL [≥6.99 mmol/L]), smoking behavior (participants were classified as current smokers, former smokers, or nonsmokers), body mass index, fasting lipid levels (low-density lipoprotein [LDL], high-density lipoprotein [HDL], and triglyceride levels), alcohol use, hematocrit values, mean systolic and diastolic blood pressures, and educational level (college vs no college). To account for the slight differences in follow-up time from visit 1 to visit 2 between study participants, exact follow-up time was also included in the multivariable analysis.STATISTICAL ANALYSISAll statistical analyses were performed using STATA statistical software (College Station, Tex). We compared baseline characteristics (ascertained at visit 1) across ABI categories. Normally distributed continuous variables were compared using the ttest; nonnormally distributed variables (eg, triglyceride levels) were compared using the Mann-Whitney Utest; and categorical variables were compared using the &khgr;2test. For all analyses, participants with an ABI of 1 or higher served as the referent category with which the other groups were compared. The association of ABI with worsening renal function was measured using bivariate and multivariate logistic regression analysis. We checked the linearity assumption for numeric predictors by including log-transformed and quadratic terms and breaking the predictor into quartiles. To satisfy the linearity assumption, triglyceride levels, systolic blood pressure, and hematocrit values were log transformed, and estimated creatinine clearance was modeled by quartile. We tested for the presence of a linear trend in the odds of a 50% increase in creatinine level across ABI categories by incorporating the categorical ABI variable into the logistic regression analysis as a numeric variable (scored 0-1-2).SENSITIVITY ANALYSESWe confirmed the presence of an association between low ABI and the study outcome after excluding, one group at a time, participants with an estimated creatinine clearance lower than 60 mL/min, diabetes, and hypertension (defined as either a mean systolic blood pressure of ≥140 mm Hg, a mean diastolic blood pressure of ≥90 mm Hg, or use of antihypertensive medication). To evaluate the impact of possible measurement error for serum creatinine on our results, we performed a companion analysis in which we defined the outcome as a 50% rise in serum creatinine level with an absolute rise in creatinine level of at least 0.4 mg/dL (35.4 μmol/L).This analysis was designed to ignore small increases in serum creatinine level occurring among cohort patients with low baseline serum creatinine levels that might be due solely to measurement error.RESULTSA total of 13 655 ARIC participantsunderwent creatinine and ABI measurement at visit 1 and creatinine measurement again at visit 2. Among these, 12 179 participants (89%) had an ABI of 1 or higher; 1105 (8%) had an ABI between 0.9 and 0.99; and 371 (3%) had an ABI lower than 0.9. Compared with the referent category of participants with an ABI of 1 or higher, the mean serum creatinine level was similar, but mean creatinine clearance was slightly lower among those with an ABI lower than 0.9 (Table 1). The relationship between baseline creatinine clearance and ABI was nonlinear: a disproportionate number of participants in the lowest and highest quartiles of creatinine clearance had low ABIs (Figure).Table 1. Baseline Characteristics by Ankle-Brachial Index (ABI)*ABI CategoryABI ≥1 (n = 12179)ABI 0.9-0.99 (n = 1105)ABI <0.9 (n = 371)Age, y54 ± 654 ± 656 ± 6†Male, %4724†35†Black, %2426 29‡Creatinine level, mg/dL (μmol/L)1.10 ± 0.3 (97.24 ± 26.5)1.08 ± 0.6 (95.47 ± 53.0)‡1.10 ± 0.2 (97.24 ± 17.7)Creatinine clearance, mL/min78 ± 1977 ± 2376 ± 21‡Diabetes, %1012 18†HDL, mg/dL (mmol/L)52 ± 17 (1.35 ± 0.44)53 ± 17 (1.37 ± 0.44)§49 ± 17 (1.27 ± 0.44)§LDL, mg/dL (mmol/L)137 ± 39 (3.55 ± 1.01)139 ± 39 (3.60 ± 1.01)148 ± 46 (3.78 ± 1.19)†Median triglycerides (range), mg/dL109 (29-1599)112 (30-1030)124 (29-1092)†Hematocrit, %41.8 ± 4.041.0 ± 3.9†41.7 ± 4.0BMI27.5 ± 5.128.3 ± 6.2†28.2 ± 6.0†Alcohol users, %5755 49†College educated or higher, %3730†27†Smoking status, % Current2331†46† Past3328†26§Blood pressure, mm Hg Systolic120 ± 18123 ± 21†126 ± 23† Diastolic73 ± 1174 ± 1272 ± 12†Antihypertensive medication, %2428†38†Follow-up, mo35.1 ± 2.735.2 ± 2.635 ± 2.4Abbreviations: BMI, body mass index (calculated as the weight in kilograms divided by the height in meters squared); HDL, high-density lipoprotein; LDL, low-density lipoprotein.SI conversion factor: To convert triglycerides to millimoles per liter, multiply by 0.0113.*Unless otherwise indicated, data are reported as mean ± SD. The referent category for Pvalue comparisons is an ABI of 1 or higher.†P<.001.‡P<.05.§P<.01.Figure.Distribution of ankle-brachial index (ABI) by approximate quartile of estimated creatinine clearance in milliliters per minute: first quartile, ≤64; second quartile, 65 to 75; third quartile, 76 to 89; fourth quartile, ≥90.Compared with participants with an ABI of 1 or higher, those with an ABI lower than 0.9 were older; included a higher percentage of women, blacks, and persons with diabetes; had lower HDL and higher LDL and triglyceride levels; had a slightly lower mean BMI; included a smaller percentage of alcohol users and college graduates and a higher percentage of current smokers; had a higher mean systolic blood pressure and lower mean diastolic blood pressure; and included a higher percentage of participants using antihypertensive medications (Table 1). Overall, serum creatinine level increased in 0.56% of participants (n = 76): 0.48% of those with an ABI of 1 or higher (n = 58), 0.9% of those with an ABI between 0.9 and 0.99 (n = 10), and 2.16% of those with an ABI lower than 0.9 (n = 8). Baseline serum creatinine levels were not significantly different among patients who did and did not experience a 50% rise in serum creatinine level (median creatinine level, 1 mg/dL [88.4 μmol/L] with 25th-75th percentile range, 0.8-1.4 mg/dL [123.8 μmol/L] vs 1.1 mg/dL [97.2 μmol/L] with 25th-75th percentile range, 1.1-1.2 mg/dL [97.2-106.1 μmol/L]) (P = .36). In both bivariate and multivariate analyses, an ABI lower than 0.9 was associated with an increase in serum creatinine level during follow-up, and there was a linear trend across ABI categories (Table 2).Table 2. Association of Baseline Ankle-Brachial Index (ABI) With Worsening Renal Function During Follow-upABIBivariate OR (CI)PValueMultivariate* OR (95% CI)PValue≥11.0 (Referent)Referent1.0 (Referent)Referent0.9-0.991.9 (0.97-3.8).061.6 (0.79-3.3).19<0.94.6 (2.2-9.7)<.0012.5 (1.06-5.7).04Pvalue for trend<.001.02Abbreviations: CI, confidence interval; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OR, odds ratio.*The following covariates ascertained at baseline were included in multivariate analysis: age, black race, sex, creatinine clearance, hematocrit value, diabetes, systolic and diastolic blood pressures, use of antihypertensive medications, HDL and LDL cholesterol values, triglyceride levels, body mass index, alcohol use, smoking status, educational level (college or higher vs other), and exact follow-up time.Results were similar after exclusion, one group at a time, of those with an estimated clearance lower than 60 mL/min (odds ratio [OR], 2.6; 95% confidence interval [CI], 1.04-6.61) (P = .04), diabetes (OR, 3.5; 95% CI, 1.2-10.5) (P = .03), and hypertension or use of antihypertensive medications (OR, 5.5; 95% CI, 1.4-21.4) (P = .02) at baseline. When we defined the outcome as a 50% rise in serum creatinine level with at least a 0.4 mg/dL (35.4 μmol/L) absolute increase in serum creatinine level (n = 66), the results did not differ substantially from the primary analysis: patients with an ABI lower than 0.9 still had a more than 2-fold adjusted risk of this outcome compared with the referent category (OR, 2.3; 95% CI, 0.92-5.8) (P = .07), and there was a trend across ABI categories (P = .03).COMMENTThe present study demonstrates that, in addition to its previously demonstrated associations with stroke, myocardial infarction, peripheral arterial disease events, and cardiovascular death,a low ABI is also associated with an increase in serum creatinine level over time. Participants with an ABI lower than 0.9 had more than 4-fold odds of experiencing a 50% rise in creatinine level compared with those with an ABI of 1 or higher, and the association persisted after adjustment for known predictors of renal functional decline. Because a low ABI is a specific measure of overall atherosclerotic burden,the existence of an association between baseline ABI and subsequent increase in serum creatinine supports the notion that preexisting atherosclerosis may be a risk factor for deterioration of renal function over time. Furthermore, the strong association of ABI with a rise in serum creatinine level in both unadjusted and adjusted analysis highlights the possible importance of ABI measurement as a means to identify patients at greatest risk for deterioration of renal function over time.Many studies have reported both cross-sectional and longitudinal associations between baseline renal insufficiency and coronary, cerebral, and peripheral arterial disease.There is also extensive research exploring possible causal mechanisms for an association between renal insufficiency and cardiovascular disease. For example, hyperhomocysteinemia, oxidant stress, elevated levels of lipoprotein(a) and inflammatory markers, and disordered calcium phosphorous metabolism all represent potential pathways for accelerated atherosclerosis in patients with renal insufficiency.There has been much less interest in the reverse association: the contribution of atherosclerosis to progression of renal disease. Using baseline data on screenees for the Multiple Risk Factor Intervention Trial (MRFIT), Klag et alreported that a history of myocardial infarction was independently associated with an increased risk of end-stage renal disease, though this was not the primary focus of the analysis. Levin et alfound that among patients with existing chronic kidney disease, the presence of cardiovascular disease predicted time to onset of end-stage renal disease. Bleyer et aldescribed a positive independent association between maximum carotid intimal thickness and subsequent rise in serum creatinine level of at least 0.3 mg/dL (26.5 μmol/L) over a 3- to 4-year period among subjects without diabetes enrolled in the Cardiovascular Health Study. Finally, a recent study by McClellan et aldemonstrated a high rate of progression to end-stage renal disease among Medicare beneficiaries hospitalized for congestive heart failure and for acute myocardial infarction.Data from several autopsy series also lend some support to the notion that systemic atherosclerosis may predispose to renal insufficiency. Among persons free of clinical renal disease and renal artery stenosis, the prevalence of glomerulosclerosis was noted to be higher among those with moderate to severe intrarenal atherosclerosis than among those with mild atherosclerosis.In a second autopsy series of persons aged 25 to 54 years, renal arteriolar hyalinization was correlated with raised lesions in the coronary arteries and aorta.While the association reported herein between low ABI and rising creatinine level may reflect a shared risk factor profile between renal disease and atherosclerosis,we were not able to explain away this association by controlling for many of the known risk factors for renal disease. Because the kidney is a highly vascular organ whose function is dependent on an intact circulatory system, it makes intuitive sense that systemic atherosclerotic disease could be causally associated with declining renal function. Based on our findings and the aforementioned studies, we would argue that systemic atherosclerosis may be a risk factor for renal insufficiency as it is for myocardial infarction, stroke, and peripheral arterial disease events.A limitation of the present study is that our definition of worsening renal function may be inaccurate owing to changes in patient age and muscle mass over time. While measured changes in creatinine clearance would probably be the best way to identify those with declining renal function, these data were not collected in ARIC.Alternate measures of declining renal function such as fixed changes in serum creatinine level, calculated clearance, or glomerular filtration rate are less clearly interpretable than a percentage change in serum creatinine level. Finally, we were unable to use incidence of new onset of renal insufficiency (defined as incidence of a calculated creatinine clearance of <60 mL/min) among patients experiencing a 50% increase in serum creatinine level because of the rarity of this outcome (n = 41) over the short follow-up period. Thus, in the absence of measured creatinine clearance, we believe that our definition of worsening renal function as a percentage rise in serum creatinine level represents the most appropriate choice.A second limitation is that our analysis did not include detailed information on the severity of important confounding comorbid conditions such as diabetes and hypertension. However, it is somewhat reassuring that even after excluding participants with diabetes or hypertension at baseline, a low ABI was still strongly associated with the study outcome.Finally, declining renal function was a relatively uncommon outcome in this sample of middle-aged community-dwelling adults. Therefore, the clinical importance of ABI measurement as a predictor of declining renal function would be best assessed in populations where worsening renal function is a more common outcome.In conclusion, a low ABI is predictive not just of recognized atherosclerotic events such as stroke, myocardial infarction, peripheral arterial disease events, and cardiovascular death, but also of rising creatinine level over time. These findings support the notion of systemic atherosclerosis as a risk factor for decline in renal function and also highlight the possible importance of ABI measurement as a means to identify patients at greatest risk for deterioration of renal function over time.Correspondence:Ann M. O'Hare, MA, MD, Veterans Affairs Medical Center, Box 111J (Nephrology), 4150 Clement St, San Francisco, CA 94121 (Ann.O'Hare@med.va.gov).Accepted for Publication:November 3, 2004.Funding/Support:Dr O'Hare is supported by a Career Development Award from the Department of Veterans Affairs Health Services Research and Development Service, Washington, DC.REFERENCESLFFriedMGShlipakCCrumpRenal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals.J Am Coll Cardiol2003411364137212706933AXGargWFClarkRBHaynesAAHouseModerate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I.Kidney Int2002611486149411918756GManjunathHTighiouartJCoreshLevel of kidney function as a risk factor for cardiovascular outcomes in the elderly.Kidney Int2003631121112912631096PMuntnerJHeLHammCLoriaPKWheltonRenal insufficiency and subsequent death resulting from cardiovascular disease in the United States.J Am Soc Nephrol20021374575311856780MGShlipakJASimonDGradyFLinNKWengerCDFurbergRenal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease.J Am Coll Cardiol20013870571111527621AMO'HareEVittinghoffJHsiaMGShlipakRenal insufficiency and the risk of lower extremity peripheral arterial disease: results from the Heart and Estrogen/Progestin Replacement Study (HERS).J Am Soc Nephrol2004151046105115034108DEWeinerHTighiouartMGAminChronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies.J Am Soc Nephrol2004151307131515100371AMO'HareDVGliddenCSFoxCYHsuHigh prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999-2000.Circulation200410932032314732743JFMannHCGersteinJPogueJBoschSYusufRenal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.Ann Intern Med200113462963611304102ASGoGMChertowDFanCEMcCullochCYHsuChronic kidney disease and the risks of death, cardiovascular events, and hospitalization.N Engl J Med20043511296130515385656FLBrancatiPKWheltonBLRandallJDNeatonJStamlerMJKlagRisk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT (Multiple Risk Factor Intervention Trial).JAMA1997278206920749403420MJKlagPKWheltonBLRandallBlood pressure and end-stage renal disease in men.N Engl J Med199633413187494564MJKlagPKWheltonBLRandallJDNeatonFLBrancatiJStamlerEnd-stage renal disease in African-American and white men: 16-year MRFIT findings.JAMA1997277129312989109467PMuntnerJCoreshJCSmithJEckfeldtMJKlagPlasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study.Kidney Int20005829330110886574JHYoungMJKlagPMuntnerJLWhyteMPahorJCoreshBlood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP).J Am Soc Nephrol2002132776278212397049MKHarounBGJaarSCHoffmanGWComstockMJKlagJCoreshRisk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland.J Am Soc Nephrol2003142934294114569104TVPernegerFLBrancatiPKWheltonMJKlagEnd-stage renal disease attributable to diabetes mellitus.Ann Intern Med19941219129187978716TVPernegerPKWheltonMJKlagRace and end-stage renal disease: socioeconomic status and access to health care as mediating factors.Arch Intern Med1995155120112087763126TVPernegerPKWheltonIBPuddeyMJKlagRisk of end-stage renal disease associated with alcohol consumption.Am J Epidemiol19991501275128110604769FCGoetzDRJacobsJrBChaversJRoelMYelleJMSprafkaRisk factors for kidney damage in the adult population of Wadena, Minnesota: a prospective study.Am J Epidemiol1997145911029006305CSFoxMGLarsonEPLeipBCulletonPWWilsonDLevyPredictors of new-onset kidney disease in a community-based population.JAMA200429184485014970063AJBleyerLRShemanskiGLBurkeKJHansenRGAppelTobacco, hypertension, and vascular disease: risk factors for renal functional decline in an older population.Kidney Int2000572072207910792626ZJZhengARSharrettLEChamblessAssociations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study.Atherosclerosis19971311151259180252GCLengFGFowkesAJLeeJDunbarEHousleyCVRuckleyUse of ankle brachial pressure index to predict cardiovascular events and death: a cohort study.BMJ1996313144014448973232ABNewmanLShemanskiTAManolioAnkle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study.Arterioscler Thromb Vasc Biol19991953854510073955RDAbbottBLRodriguezHPetrovitchAnkle-brachial blood pressure in elderly men and the risk of stroke: the Honolulu Heart Program.J Clin Epidemiol20015497397811576807JMMurabitoJCEvansMGLarsonKNietoDLevyPWWilsonThe ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study.Arch Intern Med20031631939194212963567AWTsaiARFolsomWDRosamondDWJonesAnkle-brachial index and 7-year ischemic stroke incidence: the ARIC study.Stroke2001321721172411486096The ARIC InvestigatorsThe Atherosclerosis Risk in Communities (ARIC) Study: design and objectives.Am J Epidemiol19891296877022646917DSacksCWBakalPTBeattyPosition statement on the use of the ankle-brachial index in the evaluation of patients with peripheral vascular disease: a consensus statement developed by the standards division of the society of cardiovascular & interventional radiology.J Vasc Interv Radiol20021335311932364DWCockcroftMHGaultPrediction of creatinine clearance from serum creatinine.Nephron19761631411244564ABNewmanDSSiscovickTAManolioAnkle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study.Circulation1993888378458353913KEOtahAMadanEOtahOBaderoLTClarkMOSalifuUsefulness of an abnormal ankle-brachial index to predict presence of coronary artery disease in African-Americans.Am J Cardiol20049348148314969630WSAronowCAhnPrevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women ≥62 years of age.Am J Cardiol19947464658017309MGShlipakLFFriedCCrumpCardiovascular disease risk status in elderly persons with renal insufficiency.Kidney Int200262997100412164883CZoccaliFMallamaciGTripepiTraditional and emerging cardiovascular risk factors in end-stage renal disease.Kidney Int Suppl2003JunS105S11012753278ALevinODjurdjevBBarrettCardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter.Am J Kidney Dis2001381398140711728982WMMcClellanRDLangstonRPresleyMedicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease.J Am Soc Nephrol2004151912191915213281BLKasiskeRelationship between vascular disease and age-associated changes in the human kidney.Kidney Int198731115311593599655RETracyJPStrongWPNewmanIIIGTMalcomMCOalmannMAGuzmanRenovasculopathies of nephrosclerosis in relation to atherosclerosis at ages 25 to 54 years.Kidney Int1996495645708821845MJSarnakASLeveyACSchoolwerthKidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.Circulation20031082154216914581387 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Low Ankle-Brachial Index Associated With Rise in Creatinine Level Over Time

Loading next page...
 
/lp/american-medical-association/low-ankle-brachial-index-associated-with-rise-in-creatinine-level-over-tdt01VlBz6

References (44)

Publisher
American Medical Association
Copyright
Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/archinte.165.13.1481
pmid
16009862
Publisher site
See Article on Publisher Site

Abstract

BackgroundA low ankle-brachial index (ABI) predicts risk of cardiovascular death, myocardial infarction, peripheral arterial disease events, and stroke. However, it is unknown whether a low ABI also predicts a decline in renal function.MethodsWe examined the association between ABI and change in serum creatinine level over time among 13 655 participants in the Atherosclerosis Risk in Communities (ARIC) study who underwent serum creatinine and ABI measurement at baseline and also underwent serum creatinine measurement 3 years later at the second study visit. The study outcome was a 50% rise in serum creatinine level from baseline to the second study visit.ResultsOverall, 0.48% of participants with an ABI of 1 or higher, 0.9% of participants with an ABI between 0.9 and 0.99, and 2.16% of participants with an ABI lower than 0.9 experienced a 50% or greater increase in serum creatinine level. In multivariate analysis, participants with an ABI lower than 0.9 were still more than twice as likely as those in the referent category (ABI ≥1) to experience an increase in serum creatinine level (odds ratio 2.5; 95% confidence interval, 1.1-5.7) (P = .04), and a linear trend in the incidence of worsening renal function was noted across ABI categories (P = .02). Analyses excluding participants with renal insufficiency, diabetes, and hypertension at baseline all produced similar results.ConclusionIn addition to known associations of the ABI with stroke, myocardial infarction, peripheral arterial disease events, and cardiovascular death, a low ABI also predicts an increase in serum creatinine level over time.The prevalence and incidence of cardiovascular disease are both high among those with renal insufficiency,and chronic kidney disease and cardiovascular disease share many of the same risk factors.However, the contribution of preexisting cardiovascular disease to progression of renal disease has not been examined in detail.We hypothesized that a low ankle-brachial index (ABI)—a marker for both lower extremity and more generalized atherosclerotic diseaseand a known predictor of cardiovascular death, myocardial infarction, peripheral arterial disease events, and stroke—would also be associated with a decline in renal function over time. We tested this hypothesis using publicly available data from the first and second study visits of the Atherosclerosis Risk in Communities (ARIC) study.METHODSThe ARIC studywas a prospective cohort study of cardiovascular disease among a community sample of middle-aged residents of Jackson, Miss; Forsyth County, North Carolina; Washington County, Maryland; and several suburbs of Minneapolis, Minn. The study consisted of 15 792 men and women aged 45 to 64 years at baseline. Participant recruitment and baseline data collection were completed between 1987 and 1989, and participants subsequently returned for 3 visits, each spaced 3 years apart. The present analysis uses publicly available data from the first and second study visits and was approved by the institutional review board at the University of California, San Francisco.OUTCOME MEASURE AND PREDICTOR VARIABLESThe primary predictor variable for the present analysis was ABI at the first study visit. The ABI is the ratio of systolic blood pressure at the ankle to systolic blood pressure at the brachial artery. Ankle and brachial systolic blood pressure measurements were ascertained using the Dinamap 1846 SX (Critixon, Tampa, Fla). Ankle blood pressure was measured at the posterior tibial artery in one leg. Two measurements were taken 5 to 8 minutes apart while the participant was in the prone position. Brachial artery systolic blood pressure measurements were taken 5 minutes apart with the participant in the supine position. The ABI was computed by dividing the average of the 2 ankle systolic blood pressure measurements by the average of the first 2 brachial readings. For the purposes of this analysis, we divided ABI measurements into 3 categories at the clinically established cutoffs of 0.9 and 1.0.The outcome measure for the present analysis was the occurrence of at least a 50% rise in serum creatinine level between baseline and the first follow-up visit approximately 3 years later. Too few participants experienced a doubling of serum creatinine level (a more conventional measure of renal functional decline) during follow-up for this to be used as an outcome. Regardless of initial creatinine level, a 50% increase in serum creatinine level translates into an approximately 25% decrease in creatinine clearance. This outcome is more easily interpreted than either a fixed increase in serum creatinine level or a fixed decrease in estimated creatinine clearance or glomerular filtration rate. The correlation between fixed increases in serum creatinine level and creatinine clearance is highly variable, depending on the initial creatinine level, and since values can be very inflated in patients with normal renal function, fixed decrements over time in calculated creatinine clearance or glomerular filtration rate may be misleading.Our analysis was adjusted for the following covariates ascertained at visit 1: demographic characteristics (age, race [black vs nonblack], and sex), baseline Cockcroft-Gault–estimated creatinine clearance,comorbid conditions including diabetes (previously diagnosed or fasting glucose level ≥126 mg/dL [≥6.99 mmol/L]), smoking behavior (participants were classified as current smokers, former smokers, or nonsmokers), body mass index, fasting lipid levels (low-density lipoprotein [LDL], high-density lipoprotein [HDL], and triglyceride levels), alcohol use, hematocrit values, mean systolic and diastolic blood pressures, and educational level (college vs no college). To account for the slight differences in follow-up time from visit 1 to visit 2 between study participants, exact follow-up time was also included in the multivariable analysis.STATISTICAL ANALYSISAll statistical analyses were performed using STATA statistical software (College Station, Tex). We compared baseline characteristics (ascertained at visit 1) across ABI categories. Normally distributed continuous variables were compared using the ttest; nonnormally distributed variables (eg, triglyceride levels) were compared using the Mann-Whitney Utest; and categorical variables were compared using the &khgr;2test. For all analyses, participants with an ABI of 1 or higher served as the referent category with which the other groups were compared. The association of ABI with worsening renal function was measured using bivariate and multivariate logistic regression analysis. We checked the linearity assumption for numeric predictors by including log-transformed and quadratic terms and breaking the predictor into quartiles. To satisfy the linearity assumption, triglyceride levels, systolic blood pressure, and hematocrit values were log transformed, and estimated creatinine clearance was modeled by quartile. We tested for the presence of a linear trend in the odds of a 50% increase in creatinine level across ABI categories by incorporating the categorical ABI variable into the logistic regression analysis as a numeric variable (scored 0-1-2).SENSITIVITY ANALYSESWe confirmed the presence of an association between low ABI and the study outcome after excluding, one group at a time, participants with an estimated creatinine clearance lower than 60 mL/min, diabetes, and hypertension (defined as either a mean systolic blood pressure of ≥140 mm Hg, a mean diastolic blood pressure of ≥90 mm Hg, or use of antihypertensive medication). To evaluate the impact of possible measurement error for serum creatinine on our results, we performed a companion analysis in which we defined the outcome as a 50% rise in serum creatinine level with an absolute rise in creatinine level of at least 0.4 mg/dL (35.4 μmol/L).This analysis was designed to ignore small increases in serum creatinine level occurring among cohort patients with low baseline serum creatinine levels that might be due solely to measurement error.RESULTSA total of 13 655 ARIC participantsunderwent creatinine and ABI measurement at visit 1 and creatinine measurement again at visit 2. Among these, 12 179 participants (89%) had an ABI of 1 or higher; 1105 (8%) had an ABI between 0.9 and 0.99; and 371 (3%) had an ABI lower than 0.9. Compared with the referent category of participants with an ABI of 1 or higher, the mean serum creatinine level was similar, but mean creatinine clearance was slightly lower among those with an ABI lower than 0.9 (Table 1). The relationship between baseline creatinine clearance and ABI was nonlinear: a disproportionate number of participants in the lowest and highest quartiles of creatinine clearance had low ABIs (Figure).Table 1. Baseline Characteristics by Ankle-Brachial Index (ABI)*ABI CategoryABI ≥1 (n = 12179)ABI 0.9-0.99 (n = 1105)ABI <0.9 (n = 371)Age, y54 ± 654 ± 656 ± 6†Male, %4724†35†Black, %2426 29‡Creatinine level, mg/dL (μmol/L)1.10 ± 0.3 (97.24 ± 26.5)1.08 ± 0.6 (95.47 ± 53.0)‡1.10 ± 0.2 (97.24 ± 17.7)Creatinine clearance, mL/min78 ± 1977 ± 2376 ± 21‡Diabetes, %1012 18†HDL, mg/dL (mmol/L)52 ± 17 (1.35 ± 0.44)53 ± 17 (1.37 ± 0.44)§49 ± 17 (1.27 ± 0.44)§LDL, mg/dL (mmol/L)137 ± 39 (3.55 ± 1.01)139 ± 39 (3.60 ± 1.01)148 ± 46 (3.78 ± 1.19)†Median triglycerides (range), mg/dL109 (29-1599)112 (30-1030)124 (29-1092)†Hematocrit, %41.8 ± 4.041.0 ± 3.9†41.7 ± 4.0BMI27.5 ± 5.128.3 ± 6.2†28.2 ± 6.0†Alcohol users, %5755 49†College educated or higher, %3730†27†Smoking status, % Current2331†46† Past3328†26§Blood pressure, mm Hg Systolic120 ± 18123 ± 21†126 ± 23† Diastolic73 ± 1174 ± 1272 ± 12†Antihypertensive medication, %2428†38†Follow-up, mo35.1 ± 2.735.2 ± 2.635 ± 2.4Abbreviations: BMI, body mass index (calculated as the weight in kilograms divided by the height in meters squared); HDL, high-density lipoprotein; LDL, low-density lipoprotein.SI conversion factor: To convert triglycerides to millimoles per liter, multiply by 0.0113.*Unless otherwise indicated, data are reported as mean ± SD. The referent category for Pvalue comparisons is an ABI of 1 or higher.†P<.001.‡P<.05.§P<.01.Figure.Distribution of ankle-brachial index (ABI) by approximate quartile of estimated creatinine clearance in milliliters per minute: first quartile, ≤64; second quartile, 65 to 75; third quartile, 76 to 89; fourth quartile, ≥90.Compared with participants with an ABI of 1 or higher, those with an ABI lower than 0.9 were older; included a higher percentage of women, blacks, and persons with diabetes; had lower HDL and higher LDL and triglyceride levels; had a slightly lower mean BMI; included a smaller percentage of alcohol users and college graduates and a higher percentage of current smokers; had a higher mean systolic blood pressure and lower mean diastolic blood pressure; and included a higher percentage of participants using antihypertensive medications (Table 1). Overall, serum creatinine level increased in 0.56% of participants (n = 76): 0.48% of those with an ABI of 1 or higher (n = 58), 0.9% of those with an ABI between 0.9 and 0.99 (n = 10), and 2.16% of those with an ABI lower than 0.9 (n = 8). Baseline serum creatinine levels were not significantly different among patients who did and did not experience a 50% rise in serum creatinine level (median creatinine level, 1 mg/dL [88.4 μmol/L] with 25th-75th percentile range, 0.8-1.4 mg/dL [123.8 μmol/L] vs 1.1 mg/dL [97.2 μmol/L] with 25th-75th percentile range, 1.1-1.2 mg/dL [97.2-106.1 μmol/L]) (P = .36). In both bivariate and multivariate analyses, an ABI lower than 0.9 was associated with an increase in serum creatinine level during follow-up, and there was a linear trend across ABI categories (Table 2).Table 2. Association of Baseline Ankle-Brachial Index (ABI) With Worsening Renal Function During Follow-upABIBivariate OR (CI)PValueMultivariate* OR (95% CI)PValue≥11.0 (Referent)Referent1.0 (Referent)Referent0.9-0.991.9 (0.97-3.8).061.6 (0.79-3.3).19<0.94.6 (2.2-9.7)<.0012.5 (1.06-5.7).04Pvalue for trend<.001.02Abbreviations: CI, confidence interval; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OR, odds ratio.*The following covariates ascertained at baseline were included in multivariate analysis: age, black race, sex, creatinine clearance, hematocrit value, diabetes, systolic and diastolic blood pressures, use of antihypertensive medications, HDL and LDL cholesterol values, triglyceride levels, body mass index, alcohol use, smoking status, educational level (college or higher vs other), and exact follow-up time.Results were similar after exclusion, one group at a time, of those with an estimated clearance lower than 60 mL/min (odds ratio [OR], 2.6; 95% confidence interval [CI], 1.04-6.61) (P = .04), diabetes (OR, 3.5; 95% CI, 1.2-10.5) (P = .03), and hypertension or use of antihypertensive medications (OR, 5.5; 95% CI, 1.4-21.4) (P = .02) at baseline. When we defined the outcome as a 50% rise in serum creatinine level with at least a 0.4 mg/dL (35.4 μmol/L) absolute increase in serum creatinine level (n = 66), the results did not differ substantially from the primary analysis: patients with an ABI lower than 0.9 still had a more than 2-fold adjusted risk of this outcome compared with the referent category (OR, 2.3; 95% CI, 0.92-5.8) (P = .07), and there was a trend across ABI categories (P = .03).COMMENTThe present study demonstrates that, in addition to its previously demonstrated associations with stroke, myocardial infarction, peripheral arterial disease events, and cardiovascular death,a low ABI is also associated with an increase in serum creatinine level over time. Participants with an ABI lower than 0.9 had more than 4-fold odds of experiencing a 50% rise in creatinine level compared with those with an ABI of 1 or higher, and the association persisted after adjustment for known predictors of renal functional decline. Because a low ABI is a specific measure of overall atherosclerotic burden,the existence of an association between baseline ABI and subsequent increase in serum creatinine supports the notion that preexisting atherosclerosis may be a risk factor for deterioration of renal function over time. Furthermore, the strong association of ABI with a rise in serum creatinine level in both unadjusted and adjusted analysis highlights the possible importance of ABI measurement as a means to identify patients at greatest risk for deterioration of renal function over time.Many studies have reported both cross-sectional and longitudinal associations between baseline renal insufficiency and coronary, cerebral, and peripheral arterial disease.There is also extensive research exploring possible causal mechanisms for an association between renal insufficiency and cardiovascular disease. For example, hyperhomocysteinemia, oxidant stress, elevated levels of lipoprotein(a) and inflammatory markers, and disordered calcium phosphorous metabolism all represent potential pathways for accelerated atherosclerosis in patients with renal insufficiency.There has been much less interest in the reverse association: the contribution of atherosclerosis to progression of renal disease. Using baseline data on screenees for the Multiple Risk Factor Intervention Trial (MRFIT), Klag et alreported that a history of myocardial infarction was independently associated with an increased risk of end-stage renal disease, though this was not the primary focus of the analysis. Levin et alfound that among patients with existing chronic kidney disease, the presence of cardiovascular disease predicted time to onset of end-stage renal disease. Bleyer et aldescribed a positive independent association between maximum carotid intimal thickness and subsequent rise in serum creatinine level of at least 0.3 mg/dL (26.5 μmol/L) over a 3- to 4-year period among subjects without diabetes enrolled in the Cardiovascular Health Study. Finally, a recent study by McClellan et aldemonstrated a high rate of progression to end-stage renal disease among Medicare beneficiaries hospitalized for congestive heart failure and for acute myocardial infarction.Data from several autopsy series also lend some support to the notion that systemic atherosclerosis may predispose to renal insufficiency. Among persons free of clinical renal disease and renal artery stenosis, the prevalence of glomerulosclerosis was noted to be higher among those with moderate to severe intrarenal atherosclerosis than among those with mild atherosclerosis.In a second autopsy series of persons aged 25 to 54 years, renal arteriolar hyalinization was correlated with raised lesions in the coronary arteries and aorta.While the association reported herein between low ABI and rising creatinine level may reflect a shared risk factor profile between renal disease and atherosclerosis,we were not able to explain away this association by controlling for many of the known risk factors for renal disease. Because the kidney is a highly vascular organ whose function is dependent on an intact circulatory system, it makes intuitive sense that systemic atherosclerotic disease could be causally associated with declining renal function. Based on our findings and the aforementioned studies, we would argue that systemic atherosclerosis may be a risk factor for renal insufficiency as it is for myocardial infarction, stroke, and peripheral arterial disease events.A limitation of the present study is that our definition of worsening renal function may be inaccurate owing to changes in patient age and muscle mass over time. While measured changes in creatinine clearance would probably be the best way to identify those with declining renal function, these data were not collected in ARIC.Alternate measures of declining renal function such as fixed changes in serum creatinine level, calculated clearance, or glomerular filtration rate are less clearly interpretable than a percentage change in serum creatinine level. Finally, we were unable to use incidence of new onset of renal insufficiency (defined as incidence of a calculated creatinine clearance of <60 mL/min) among patients experiencing a 50% increase in serum creatinine level because of the rarity of this outcome (n = 41) over the short follow-up period. Thus, in the absence of measured creatinine clearance, we believe that our definition of worsening renal function as a percentage rise in serum creatinine level represents the most appropriate choice.A second limitation is that our analysis did not include detailed information on the severity of important confounding comorbid conditions such as diabetes and hypertension. However, it is somewhat reassuring that even after excluding participants with diabetes or hypertension at baseline, a low ABI was still strongly associated with the study outcome.Finally, declining renal function was a relatively uncommon outcome in this sample of middle-aged community-dwelling adults. Therefore, the clinical importance of ABI measurement as a predictor of declining renal function would be best assessed in populations where worsening renal function is a more common outcome.In conclusion, a low ABI is predictive not just of recognized atherosclerotic events such as stroke, myocardial infarction, peripheral arterial disease events, and cardiovascular death, but also of rising creatinine level over time. These findings support the notion of systemic atherosclerosis as a risk factor for decline in renal function and also highlight the possible importance of ABI measurement as a means to identify patients at greatest risk for deterioration of renal function over time.Correspondence:Ann M. O'Hare, MA, MD, Veterans Affairs Medical Center, Box 111J (Nephrology), 4150 Clement St, San Francisco, CA 94121 (Ann.O'Hare@med.va.gov).Accepted for Publication:November 3, 2004.Funding/Support:Dr O'Hare is supported by a Career Development Award from the Department of Veterans Affairs Health Services Research and Development Service, Washington, DC.REFERENCESLFFriedMGShlipakCCrumpRenal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals.J Am Coll Cardiol2003411364137212706933AXGargWFClarkRBHaynesAAHouseModerate renal insufficiency and the risk of cardiovascular mortality: results from the NHANES I.Kidney Int2002611486149411918756GManjunathHTighiouartJCoreshLevel of kidney function as a risk factor for cardiovascular outcomes in the elderly.Kidney Int2003631121112912631096PMuntnerJHeLHammCLoriaPKWheltonRenal insufficiency and subsequent death resulting from cardiovascular disease in the United States.J Am Soc Nephrol20021374575311856780MGShlipakJASimonDGradyFLinNKWengerCDFurbergRenal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease.J Am Coll Cardiol20013870571111527621AMO'HareEVittinghoffJHsiaMGShlipakRenal insufficiency and the risk of lower extremity peripheral arterial disease: results from the Heart and Estrogen/Progestin Replacement Study (HERS).J Am Soc Nephrol2004151046105115034108DEWeinerHTighiouartMGAminChronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies.J Am Soc Nephrol2004151307131515100371AMO'HareDVGliddenCSFoxCYHsuHigh prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999-2000.Circulation200410932032314732743JFMannHCGersteinJPogueJBoschSYusufRenal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.Ann Intern Med200113462963611304102ASGoGMChertowDFanCEMcCullochCYHsuChronic kidney disease and the risks of death, cardiovascular events, and hospitalization.N Engl J Med20043511296130515385656FLBrancatiPKWheltonBLRandallJDNeatonJStamlerMJKlagRisk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT (Multiple Risk Factor Intervention Trial).JAMA1997278206920749403420MJKlagPKWheltonBLRandallBlood pressure and end-stage renal disease in men.N Engl J Med199633413187494564MJKlagPKWheltonBLRandallJDNeatonFLBrancatiJStamlerEnd-stage renal disease in African-American and white men: 16-year MRFIT findings.JAMA1997277129312989109467PMuntnerJCoreshJCSmithJEckfeldtMJKlagPlasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study.Kidney Int20005829330110886574JHYoungMJKlagPMuntnerJLWhyteMPahorJCoreshBlood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP).J Am Soc Nephrol2002132776278212397049MKHarounBGJaarSCHoffmanGWComstockMJKlagJCoreshRisk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland.J Am Soc Nephrol2003142934294114569104TVPernegerFLBrancatiPKWheltonMJKlagEnd-stage renal disease attributable to diabetes mellitus.Ann Intern Med19941219129187978716TVPernegerPKWheltonMJKlagRace and end-stage renal disease: socioeconomic status and access to health care as mediating factors.Arch Intern Med1995155120112087763126TVPernegerPKWheltonIBPuddeyMJKlagRisk of end-stage renal disease associated with alcohol consumption.Am J Epidemiol19991501275128110604769FCGoetzDRJacobsJrBChaversJRoelMYelleJMSprafkaRisk factors for kidney damage in the adult population of Wadena, Minnesota: a prospective study.Am J Epidemiol1997145911029006305CSFoxMGLarsonEPLeipBCulletonPWWilsonDLevyPredictors of new-onset kidney disease in a community-based population.JAMA200429184485014970063AJBleyerLRShemanskiGLBurkeKJHansenRGAppelTobacco, hypertension, and vascular disease: risk factors for renal functional decline in an older population.Kidney Int2000572072207910792626ZJZhengARSharrettLEChamblessAssociations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study.Atherosclerosis19971311151259180252GCLengFGFowkesAJLeeJDunbarEHousleyCVRuckleyUse of ankle brachial pressure index to predict cardiovascular events and death: a cohort study.BMJ1996313144014448973232ABNewmanLShemanskiTAManolioAnkle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study.Arterioscler Thromb Vasc Biol19991953854510073955RDAbbottBLRodriguezHPetrovitchAnkle-brachial blood pressure in elderly men and the risk of stroke: the Honolulu Heart Program.J Clin Epidemiol20015497397811576807JMMurabitoJCEvansMGLarsonKNietoDLevyPWWilsonThe ankle-brachial index in the elderly and risk of stroke, coronary disease, and death: the Framingham Study.Arch Intern Med20031631939194212963567AWTsaiARFolsomWDRosamondDWJonesAnkle-brachial index and 7-year ischemic stroke incidence: the ARIC study.Stroke2001321721172411486096The ARIC InvestigatorsThe Atherosclerosis Risk in Communities (ARIC) Study: design and objectives.Am J Epidemiol19891296877022646917DSacksCWBakalPTBeattyPosition statement on the use of the ankle-brachial index in the evaluation of patients with peripheral vascular disease: a consensus statement developed by the standards division of the society of cardiovascular & interventional radiology.J Vasc Interv Radiol20021335311932364DWCockcroftMHGaultPrediction of creatinine clearance from serum creatinine.Nephron19761631411244564ABNewmanDSSiscovickTAManolioAnkle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study.Circulation1993888378458353913KEOtahAMadanEOtahOBaderoLTClarkMOSalifuUsefulness of an abnormal ankle-brachial index to predict presence of coronary artery disease in African-Americans.Am J Cardiol20049348148314969630WSAronowCAhnPrevalence of coexistence of coronary artery disease, peripheral arterial disease, and atherothrombotic brain infarction in men and women ≥62 years of age.Am J Cardiol19947464658017309MGShlipakLFFriedCCrumpCardiovascular disease risk status in elderly persons with renal insufficiency.Kidney Int200262997100412164883CZoccaliFMallamaciGTripepiTraditional and emerging cardiovascular risk factors in end-stage renal disease.Kidney Int Suppl2003JunS105S11012753278ALevinODjurdjevBBarrettCardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter.Am J Kidney Dis2001381398140711728982WMMcClellanRDLangstonRPresleyMedicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease.J Am Soc Nephrol2004151912191915213281BLKasiskeRelationship between vascular disease and age-associated changes in the human kidney.Kidney Int198731115311593599655RETracyJPStrongWPNewmanIIIGTMalcomMCOalmannMAGuzmanRenovasculopathies of nephrosclerosis in relation to atherosclerosis at ages 25 to 54 years.Kidney Int1996495645708821845MJSarnakASLeveyACSchoolwerthKidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.Circulation20031082154216914581387

Journal

JAMA Internal MedicineAmerican Medical Association

Published: Jul 11, 2005

There are no references for this article.